|
Chantix contains the active ingredient, varenicline, as
tartarate salt that is in powder form. Inactive ingredients
are microcrystalline cellulose, anhydrous dibasic calcium
phosphate, croscarmellose sodium, colloidal silicon dioxide,
and magnesium. When smokers inhale from a cigarette, the
nicotine binds to receptors in the brain, which have an
affinity for nicotine. Similar to the effects of inhaling a
cigarette, Chantrix binds with receptors in the brain that
have a high affinity for nicotine.
Chentix is designed to
partially activate the nicotine receptor in the brain to
reduce the craving for cigarettes and also reduce the
severity of withdrawal symptoms. Chentix blocks the ability
of the nicotine to activate the brain receptors and
stimulates the central nervous system that reinforces and
rewards the experiences of
smokeing. Maximum blood
concentrations occur within 3-4 hours after taking Chantix.
After multiple does of
Chantrix, a stable state of effects was reached within four
days.
The prescribed course of
treatment is twelve days combined with an educational
program the benefits of quitting smoking. Patients who have
successfully quit smoking over the twelve-week period are
given an additional twelve-week protocol to insure long-term
success in quitting smoking. If a patient does begin smoking
during the twelve-week treatment, Chantix can reduce the
satisfaction and reward of smoking. Because smoking produces
a cycle of nicotine craving followed by withdrawal after the
initial effects have dissipated, Chantix can diminish the
satisfaction related to smoking and break the cycle of
addiction to nicotine.
Patients who
participated in the clinical trials reported a reduction in
nicotine cravings and eventual cessation of smoking.
|
|
